These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30519542)

  • 1. Patient Preferences Regarding Chemotherapy in Metastatic Breast Cancer-A Conjoint Analysis for Common Taxanes.
    Spaich S; Kinder J; Hetjens S; Fuxius S; Gerhardt A; Sütterlin M
    Front Oncol; 2018; 8():535. PubMed ID: 30519542
    [No Abstract]   [Full Text] [Related]  

  • 2. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
    J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
    Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
    Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer.
    daCosta DiBonaventura M; Copher R; Basurto E; Faria C; Lorenzo R
    Am Health Drug Benefits; 2014 Oct; 7(7):386-96. PubMed ID: 25525495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists.
    Rocque GB; Rasool A; Williams BR; Wallace AS; Niranjan SJ; Halilova KI; Turkman YE; Ingram SA; Williams CP; Forero-Torres A; Smith T; Bhatia S; Knight SJ
    Oncologist; 2019 Oct; 24(10):1313-1321. PubMed ID: 30872466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
    Gennari A; Sun Z; Hasler-Strub U; Colleoni M; Kennedy MJ; Von Moos R; Cortés J; Vidal MJ; Hennessy B; Walshe J; Parraga KA; Ribi K; Bernhard J; Murillo SM; Pagani O; Barbeaux A; Borstnar S; Rabaglio-Poretti M; Maibach R; Regan MM; Jerusalem G;
    Ann Oncol; 2018 Mar; 29(3):661-668. PubMed ID: 29228091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
    Vernieri C; Milano M; Mennitto A; Maggi C; Ferrari B; Rinaldi L; Mennitto R; Stefanetti C; Re B; Mariani G; Bianchi G; Capri G; de Braud F
    Breast Cancer Res Treat; 2017 Sep; 165(2):365-373. PubMed ID: 28616768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis.
    Dong L; Zhu LN; Xie BJ; Li JB; Ding T; Jiang YF; Zhu ZN
    Pharmacotherapy; 2019 Dec; 39(12):1126-1136. PubMed ID: 31692005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G; Coleman R; Gradishar W
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
    González-Martín A; Alba E; Ciruelos E; Cortés J; Llombart A; Lluch A; Andrés R; Álvarez I; Aramendía JM; de la Peña FA; Barnadas A; Batista N; Calvo L; Galve E; García-Palomo A; García-Sáenz JÁ; de la Haba J; López R; López-Vivanco G; Martínez-Jáñez N; de Dueñas EM; Plazaola A; Rodríguez-Lescure Á; Ruiz M; Sánchez-Rovira P; Santaballa A; Seguí MÁ; Tusquets I; Zamora P; Martín M
    Curr Cancer Drug Targets; 2016; 16(5):415-28. PubMed ID: 26278712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Curr Med Res Opin; 2013 Feb; 29(2):117-25. PubMed ID: 23216340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
    Oh WK; Manola J; Babcic V; Harnam N; Kantoff PW
    Urology; 2006 Jun; 67(6):1235-40. PubMed ID: 16765185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
    Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force.
    Biganzoli L; Aapro M; Loibl S; Wildiers H; Brain E
    Cancer Treat Rev; 2016 Feb; 43():19-26. PubMed ID: 26827689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.